论文部分内容阅读
对于胰腺癌从Whipple切除术到RTOGⅠ/Ⅱ期术中放射治疗的研究,它的治疗结果仍然是令人沮丧的。当今将1ORT看作是治疗胰腺癌的希望。因为以前的技术使用外照射结合间质植入,加上或者不加化疗,已使胰腺癌仅3至7个月的中位存活有所提高。最初使用1ORT是由Abe和Goldson报道的,使用单次剂量20～40Gy,中位存活期是6个月。最初IORT做为一个“追加剂量”结合外放射来自麻省总医院和Mayo诊所,对于不能手术切除的胰腺癌得到中位存活13.5个月,日本与美国其他
For the study of pancreatic cancer from Whipple resection to RTOGI/II intraoperative radiotherapy, its treatment results are still frustrating. Today, 1 ORT is seen as a hope for the treatment of pancreatic cancer. Because previous techniques used external irradiation combined with mesenchymal implantation, with or without chemotherapy, the median survival of pancreatic cancer was only improved from 3 to 7 months. The initial use of 1ORT was reported by Abe and Goldson, using a single dose of 20-40 Gy, with a median survival of 6 months. Initially IORT as an “additional dose” combined with external radiation from Massachusetts General Hospital and Mayo Clinic, median survival for 13.5 months for non-surgical pancreatic cancer, Japan and the United States